2025年1月13日,先声药业(02096.HK,股价6.58港元,市值166亿港元)旗下抗肿瘤创新药公司先声再明宣布,已与全球制药公司艾伯维(AbbVie)就先声再明正在中美两国进行临床I期研究的多发性骨髓瘤(MM)候选药物SIM0500达成开发许可选择协议。 本次牵手的焦点在于先声再明自主研发的SIM0500,这是一款人源化的GPRC5D-BCMA-CD3三特异性抗体。目前,该药物已经在中美...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.